Akari Therapeutics Plc
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
DilutionScan read 41 of Akari Therapeutics Plc's SEC filings and found 35 warrant series, 2 convertibles, 1 equity line, 5 shelf registrations, 4 S-1 registrations and 5 completed offerings on file for AKTX. The latest dilution event on file is a registration statement on Jul 13, 2026. Analysis updated Oct 21, 2026.
Signal8 Summary
AKTX
Cash runway under 2 months with expected impairment
Snapshot
Akari Therapeutics is a clinical-stage biotech with no revenue and a strained balance sheet. The company burned $17.3 million in net income during FY 2025 and holds only $5.2 million in cash. At its current burn rate, that cash lasts approximately 1.5 months. The company recently raised $5.5 million through a private placement, which extends the runway but comes with significant dilution.
What's Happening Right Now
- : Akari priced a $5.5 million private placement to fund its lead cancer drug candidate, AKTX-101, toward a Phase 1 trial.
- : Akari reported positive preclinical data showing its lead drug works synergistically with existing KRAS inhibitors in pancreatic cancer models.
- : The company delayed its quarterly report and warned of a material non-cash impairment charge due to its collapsing market value.
- : Akari announced a strategic partnership with WuXi XDC to accelerate the development of its novel antibody-drug conjugate payload.
- : The company executed a 1-for-40 reverse stock split in March 2026, a move typically taken by stocks under severe price pressure.
